# US 2021/0171469 A1 · Inhibitors of the notch transcriptional activation complex kinase ("nack") and methods for use of the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171469 A1
- Document ID: US20210171469A1
- Status: Published application
- Kind: A1
- Application number: 16/967,652
- Filed: 2019-02-06
- Published: 2021-06-10
- Earliest claimed: 2018-02-06
- Assignees: University of Miami
- Applicants: University of Miami
- Inventors: Anthony J. Capobianco; Stephan C. Schürer; Xiaoxia Zhu; Tanya T. Kelley
- Web page: https://patentgrep.com/patent/US20210171469A1

## CPC

- C07D 231/54: condensed with carbocyclic rings or ring systems
- C07D 471/04: Ortho-condensed systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12Y 207/00: Transferases transferring phosphorus-containing groups (2.7)
- C12Y 306/01003: Adenosine triphosphatase (3.6.1.3)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Disclosed herein are Notch transcriptional activation complex kinase (“NACK”) inhibitors, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein include compounds of Formula (la) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

## Claims

### Claim 1

A compound of Formula (Ia), or a pharmaceutically acceptable salt thereof:
wherein:
A is C1-4alkyl or
X is CH or N;
Y is CH2 or N, and when X is N, then Y is CH2;
m is 0 or 1, and when m is 1 then Y is CH2;
n is 0 or 1;
R1 is H, C1-6alkyl, C0-6alkyleneC(═O)R6, halo, cyano, aryloxy, amino, C0-3alkylene-amido, carbamyl, S-thiocarbamyl, or ureido;
R2 is H, halo, C1-6alkyl, C3-8cycloalkyl, or heteroaryl;
each R3 and R4 independently is H, C1-6 alkyl, or C1-3aralkyl, or R3 and R4 and the nitrogen to which they are attached join together to form a 3-6 membered ring optionally comprising 1 to 3 additional heteroatoms selected from N, O, and S;
R5 is H, or R1 and R5 together with the atoms to which they are attached form a 5- or 6-membered heterocyclic ring comprising 1 to 3 ring heteroatoms selected from N, O, and S;
R6 is OH, C1-6alkyl, or OC1-6alkyl; and
R7 is H, halo or amino;
with the proviso that the compound is not

### Claim 2 (depends on 1)

The compound of claim 1, wherein A is methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, isobutyl, or t-butyl.

### Claim 3 (depends on 2)

The compound or salt of claim 2, wherein A is methyl.

### Claim 4 (depends on 1)

The compound or salt of claim 1, wherein A is

### Claim 5 (depends on 4)

The compound or salt of claim 4, wherein n is 0.

### Claim 6 (depends on 4)

The compound or salt of claim 4, wherein n is 1.

### Claim 7 (depends on 4, 5, 6)

The compound or salt of any one of claims 4-6, wherein R1 and R5 together with the atoms to which they are attached form a 5- or 6-membered heterocyclic ring comprising 1 to 3 ring heteroatoms selected from N, O, and S.

### Claim 8 (depends on 7)

The compound of claim 7, wherein A is selected from the group consisting of

### Claim 9 (depends on 4, 5, 6)

The compound or salt of any one of claims 4-6, wherein R5 is H.

### Claim 10 (depends on 9)

The compound or salt of claim 9, wherein R1 is H.

### Claim 11 (depends on 9)

The compound or salt of claim 9, wherein R1 is C1-6alkyl.

### Claim 12 (depends on 11)

The compound or salt of claim 11, wherein R1 is methyl, ethyl, fluoromethyl, or trifluoromethyl.

### Claim 13 (depends on 9)

The compound or salt of claim 9, wherein R1 is C0-6alkyleneC(═O)R6.

### Claim 14 (depends on 13)

The compound of claim 13, wherein, R1 is

### Claim 15 (depends on 9)

The compound or salt of claim 9, wherein R1 is halo.

### Claim 16 (depends on 15)

The compound or salt of claim 15, wherein R1 is F.

### Claim 17 (depends on 9)

The compound or salt claim 9, wherein R1 is cyano or aryloxy.

### Claim 18 (depends on 17)

The compound or salt of claim 17, wherein R1 is CN or —OPh.

### Claim 19 (depends on 9)

The compound or salt of claim 9, wherein R1 is amino.

### Claim 20 (depends on 19)

The compound or salt of claim 19, wherein R1 is —NH2, —N(CH3)2 or —NH2Ph.

### Claim 21 (depends on 9)

The compound or salt of claim 9, wherein R1 is C0-3alkylene-amido, carbamyl, S-thiocarbamyl, or ureido.

### Claim 22 (depends on 21)

The compound or salt of claim 21, wherein R1 is selected from the group consisting of

### Claim 23 (depends on 1)

The compound or salt of claim 1, wherein A is selected from the group consisting of CH3,

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound or salt of any one of claims 1-23, wherein X is CH.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound or salt of any one of claims 1-23, wherein X is N.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound or salt of any one of claims 1-25, wherein Y is CH2.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound or salt of any one of claims 1-24, wherein Y is N.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound or salt of any one of claims 1-27, wherein m is 0.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound or salt of any one of claims 1-27, wherein m is 1.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound or salt of any one of claims 1-29, wherein R2 is H.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound or salt of any one of claims 1-29, wherein R2 is Br or Cl.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound or salt of any one of claims 1-29, wherein R2 is CH3, CF3, CH2OH, or CH2OCH3.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound or salt of any one of claims 1-29, wherein R2 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound or salt of any one of claims 1-29, wherein R2 is 3-furanyl.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound or salt of any one of claims 1-29, wherein R2 is selected from the group consisting of H, CH3, CF3, and cyclopropyl.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The compound or salt of any one of claims 1-35, wherein each of R3 and R4 independently is H, C1-6 alkyl, or C1-3aralkyl.

### Claim 37 (depends on 36)

The compound or salt of claim 36, wherein each of R3 and R4 independently is H, CH3, CH2CH3, iBu, or CH2Ph.

### Claim 38 (depends on 35)

The compound or salt of claim 35, wherein
is selected from the group consisting of

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The compound or salt of any one of claims 1-35, wherein R3 and R4 and the nitrogen to which they are attached join together to form a 5-6 membered ring.

### Claim 40 (depends on 39)

The compound or salt of claim 39, wherein
is selected from the group consisting of

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The compound or salt of any one of claims 1-35, wherein
is selected from the group consisting of

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The compound or salt of any one of claims 1-41, wherein R7 is H.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The compound or salt of any one of claims 1-41, wherein R7 is NH2, Br, Cl, or F.

### Claim 44

A compound listed in Table A, Table B, Table C, or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A pharmaceutical composition comprising a compound of any one of claims 1-44 and a pharmaceutically acceptable excipient.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method of inhibiting the Notch activation complex kinase (“NACK”) in a cell, comprising contacting the cell with a compound of any one of claims 1-44, the pharmaceutical composition of claim 45,
or a pharmaceutically acceptable salt of any of the foregoing, in an amount effective to inhibit NACK.

### Claim 47 (depends on 46)

The method of claim 46, wherein the compound inhibits NACK recruitment to the Notch transcriptional complex (“NTC”).

### Claim 48 (depends on 46, 47)

The method of claim 46 or 47, wherein the contacting comprises administering to a patient in need thereof.

### Claim 49 (depends on 48)

The method of claim 48, wherein the patient suffers from a disease associated with deregulation of the Notch transcriptional activation complex.

### Claim 50 (depends on 49)

The method of claim 49, wherein the disease is Tetralogy of Fallot (“TOF”) or Alagille syndrome.

### Claim 51 (depends on 49)

The method of claim 49, wherein the disease is cancer.

### Claim 52 (depends on 51)

The method of claim 51, wherein the cancer is selected from the group consisting of T-cell acute lymphoblastic leukemia (“T-ALL”), B-cell acute lymphoblastic leukemia (“B-ALL”), breast cancer, medulloblastoma, colorectal cancer, non-small cell lung carcinoma (“NSCLC”), melanoma, cerebral autosomal-dominant ateriopathy with sub-cortical infarcts and leukoencephalophathy (“CADASIL”), chronic lymphocytic leukemia (“CLL”), hepatocellular carcinoma (“HOC”), myelomonocytic leukemia (“CMML”), pancreatic ductal adenocarcinoma (“PDAC”), multiple sclerosis (“MS”), head and neck squamous cell carcinoma (“HNSCC”), renal cell adenocarcinoma, and fibrosarcoma.

### Claim 53 (depends on 49)

The method of claim 49, wherein the disease is multiple sclerosis (“MS”).

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method of inhibiting kinase activity, ATPase activity, or both in a cell, comprising contacting the cell with a compound of any one of claims 1-44, the pharmaceutical composition of claim 45,
or a pharmaceutically acceptable salt of any of the foregoing in an amount effective to inhibit kinase activity, ATPase activity, or both in the cell.
